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Background: CLP is an orally administered, non-absorbed, superabsorbent polymer being developed to increase
fecal excretion of sodium, potassium and water in patients with heart failure and end-stage renal disease. This study
was conducted to evaluate the safety of CLP, and to explore dose-related effects on fecal weight, fecal and urine
sodium and potassium excretion, and serum electrolyte concentrations.
Methods: This Phase 1, open-label, dose-escalation study included 25 healthy volunteers, who were administered
CLP orally immediately prior to four daily meals for 9 days at doses of 7.5, 15.0, and 25.0 g/day (n = 5/group). An
additional dose group received 15.0 g/day CLP under fasting conditions, and an untreated cohort (n = 5) served as
control. Twenty-four-hour fecal and urinary output was collected daily. Samples were weighed, and sodium,
potassium, and other ion content in stool and urine were measured for each treatment group. Effects on serum
cation concentrations, other standard laboratory values, and adverse events were also determined.
Results: At doses below 25.0 g/day, CLP was well tolerated, with a low frequency of self-limiting gastrointestinal
adverse events. CLP increased fecal weight and fecal sodium and potassium content in a dose-related manner.
Concomitant dose-related decreases in urinary sodium and potassium were observed. All serum ion concentrations
remained within normal limits.
Conclusions: In this study, oral CLP removed water, sodium and potassium from the body via the gastrointestinal
tract in a dose related fashion. CLP could become useful for patients with fluid overload and compromised kidney
function in conditions such as congestive heart failure, salt sensitive hypertension, chronic kidney disease and end
stage renal disease.
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Fluid overload and sodium retention are central compo-
nents in the pathophysiology of heart failure, with up to
90% of hospitalizations in heart failure caused by symp-
toms and signs of fluid overload [1,2]. There is also
growing evidence that hypervolemia per se is independ-
ently associated with mortality [3,4]. Concomitant renal
dysfunction (chronic kidney disease; CKD) has a strong
association with poor outcomes in heart failure patients
[5,6]. Diuretics are the cornerstone of acute and chronic
heart failure therapy, but concerns have been raised about
the safety and therapeutic efficacy of high dose diuretic
therapy [2,7-9], diuretic resistance in the presence of
declining renal function and undesired serum electro-
lyte effects [10,11]. The use of cationic exchange resins
for removal of excess sodium and water via the gastro-
intestinal tract from edematous patients was under con-
siderable study in the late 1940s and early 1950s [12].
These products failed to achieve a significant therapeutic
presence, in large measure due to the high dosage re-
quired (up to 150 g/day), problems in taking the large
amounts of unpalatable resins, significant abdominal side
effects and the advent of loop diuretics. Recently, interest
in the use of the gastrointestinal tract to remove fluid and/
or ions using polymers of enhanced efficacy and improved
tolerability has been renewed [13,14].
New treatment options for fluid and ion management
are a significant medical need [2]. CLP (Cross Linked
Polyelectrolyte) is a novel, non-absorbed, superabsor-
bent polymer that, given orally, absorbs water, sodium
and potassium in the gastrointestinal tract with eventual
elimination in the feces. The clinical effects of CLP in
patients with congestive heart failure and impaired kidney
function were recently reported in a Phase 2, double-
blind, placebo-controlled study. Patients administered
15 g/day CLP lost significantly more weight, had a
higher proportion of improvement in New York Heart
Association (NYHA) class and showed a trend for im-
provement in both the six minute walk test and the
Kansas City Cardiomyopathy Questionnaire compared to
patients receiving placebo [13]. This exploratory Phase 1
study was done before the Phase 2 study and the purpose
was to evaluate the safety of CLP, and to explore the dose-
related effects on fecal weight, and urine and fecal sodium
and potassium excretion.Methods
The study was conducted in accordance with Inter-
national Conference on Harmonisation Good Clinical
Practice guidelines and other applicable regulatory re-
quirements and laws. The study protocol was reviewed
and approved by the IntegReview Ethical Review Board,
Austin, Texas. All subjects provided written informedconsent prior to study participation. Trial registration
number: NCT01944007.
Healthy volunteers at least 18 years of age considered
to be in good general health (no renal, cardiac, hepatic or
other major organ dysfunction) and with no prior history
of major gastrointestinal surgery, conditions affecting mo-
tility, or dyspepsia requiring treatment within the previous
6 months were recruited by the Clinical Pharmacology
Research Unit at the Jasper Clinic, Kalamazoo, Michigan.
This Phase 1, open-label, dose-escalation study recruited
25 healthy volunteers who were randomized into five
groups (n = 5/group): a) Control (untreated), b) 7.5 g CLP/
day, c) 15.0 g CLP/day, d) 15.0 g CLP/day (fasted) and
e) 25.0 g CLP/day. CLP was administered orally in size
00 hydroxypropylmethylcellulose capsules immediately
prior to meals (breakfast, lunch, dinner, and snack) in 4
doses divided equally for 9 days, except in the 15.0 g/day
fasted group who received the medication 1 hour prior to
meals to evaluate the effects of CLP on an empty stomach.
With the exception of administration of study medication,
untreated control subjects were exposed to the same con-
ditions and procedures as CLP subjects. All subjects were
given identical, standardized meals that were controlled
for the amount of calories, level of sodium (~5000 mg
per day ±100 mg), fiber content (10-15 g per day), fat
content, and approximate recommended Dietary Reference
Intakes. The study subjects were requested to consume
all of their meals. Clinic staff monitored and recorded
complete ingestion of the meals served during the study.
All fluid intake was recorded.
Subjects were admitted to the research unit on Day -1
(baseline); CLP was administered on Days 1 through 9,
and subjects were discharged on Day 10.
Fecal and urine samples for each 24-hour period were
collected daily during the treatment period and were
weighed and analyzed for sodium, potassium, magnesium,
calcium, and phosphorus. Daily samples were pooled
for analysis. Analyses of ion content in feces were per-
formed by inductively coupled plasma-optical emission
spectroscopy (ICP-OES) at Galbraith Labs Inc. (Knoxville,
Tennessee). Urine samples and safety laboratories were
analyzed at Bronson Methodist Hospital Laboratory
(Kalamazoo, Michigan), using standard clinical auto-
mated chemistry techniques.
Safety assessments included daily monitoring of adverse
events, vital signs and serum chemistries. Hematology,
urinalysis, and 12-lead electrocardiogram (ECG) were
measured at baseline and prior to discharge. All blood
samples were drawn in the fasting stage before breakfast.
Endpoints
Endpoints to evaluate the pharmacologic activity of CLP
included stool weight, fecal content of sodium, potassium,
calcium, magnesium and phosphorus, and urine content
Henderson et al. BMC Pharmacology and Toxicology 2014, 15:2 Page 3 of 7
http://www.biomedcentral.com/2050-6511/15/2of sodium, potassium, calcium, magnesium and phos-
phorus. Safety and tolerability evaluations were based
on frequency and severity of adverse events, clinical
safety labs and vital signs.
Statistical analysis
Fecal ion content, fecal weight, urine ion content and
serum ion concentration data were summarized for each
CLP dose group and the control group using descriptive
statistics for an empirically determined steady state
period (Days 5-9). The steady state period is illustrated
for stool weight for the 15 g/day fed group in Figure 1.
Due to the exploratory nature of the study and the small
sample size, no formal confirmatory statistical analysis
was performed.
For these descriptive statistical analyses, data collected
during the steady-state period were analyzed as the daily
average of values measured on Days 5-9. Least squares
mean profiles and empirical standard errors for each CLP
dose group versus control were estimated via generalized
estimating equations in accordance with a 2-group re-
peated measures analysis of variance (RM-ANOVA) as-
suming compound symmetry. The least squares means
and corresponding 95% confidence intervals from the
RM-ANOVA were then used to depict expected cumu-
lative (Days 5-9) mean values for each pairing of CLP
versus control. The incidence of treatment-emergent ad-
verse events for each group was determined. Hematology,
serum chemistry and quantitative urinalysis analytes were
summarized by treatment group using descriptive statis-
tics; qualitative urinalysis analytes were summarized by
treatment group. Descriptive statistics were performed on
vital signs data for each treatment group. ECG data wereFigure 1 Daily fecal weight following 15.0 g/day CLP for 9 days unde
line indicates start of steady state.summarized for each treatment group as normal or abnor-
mal; abnormal findings were categorized further with
regard to clinical significance.
Results
Subjects ranged in age from 22 to 68 years (mean,
38.0 years). Approximately half of the subjects (56%) were
male, and dose groups were not balanced with regard to
gender: the control group comprised only females, and all
but the 15.0 g/day fed group, which included 2 males and
3 females, had a male to female ratio of 4:1. The sample
was predominantly Caucasian (84% of subjects).
Fecal weight
Mean fecal weight was higher in all CLP groups com-
pared to the control group during study Days 5-9. Mean
fecal weight values increased in a dose-related manner
and were similar in the fed and fasted 15.0 g/day CLP
groups (Figure 2).
Fecal ion content
Mean fecal sodium and potassium content were higher in
all CLP groups compared to the control group (Figure 3),
and increased in a dose-related manner. Mean fecal mag-
nesium and calcium content were similar across treatment
groups and fecal phosphorus was lower than the control
group at 15.0 g/day. No differences between fed and fasted
state were noted for fecal content of any of the ions.
Urine ion content
Mean urine sodium and potassium were lower in all
CLP groups than the control group, with values in CLP
groups showing an inverse relationship to dose (Figure 4).r fed conditions. Values are means ± 95% confidence intervals. Blue
Figure 2 Mean (standard deviation) fecal weight by treatment
group. Values are daily averages from Days 5-9, the time period
reflective of steady state CLP exposure.
Henderson et al. BMC Pharmacology and Toxicology 2014, 15:2 Page 4 of 7
http://www.biomedcentral.com/2050-6511/15/2Treatment groups were similar with respect to urine cal-
cium and magnesium, whereas there was an increase in
urine phosphorus content at higher doses. There were no
noteworthy differences in mean urine cation content
values under fed versus fasting conditions.Serum ion concentrations
There were no clinically meaningful changes in mean
serum ion concentrations during the study. A dose
dependent drop in serum potassium resulted in a bor-
derline low serum potassium level in the 25.0 g/day
CLP group (Table 1).Figure 3 Mean (standard deviation) fecal content of sodium and pota
daily averages from Days 5-9, the time period reflective of steady state CLPSafety
Adverse events
No serious adverse events were reported. At doses below
25.0 g/day, CLP was well tolerated. Two subjects in the
25.0 g/day group discontinued CLP dosing on Day 4 due
to gastrointestinal adverse events: one due to repeated epi-
sodes of moderately severe vomiting, and the other due to
abdominal distension, nausea and abdominal pain. Events
for both subjects resolved completely without medical
treatment prior to discharge on Day 9, five days after ter-
mination of dosing. The most frequently reported adverse
events were gastrointestinal in nature and appeared to be
dose related. However, gastrointestinal adverse events
were also reported for 4 of 5 subjects in the control group.
The most common gastrointestinal event was nausea.
Diarrhea was reported for 1 subject each in the 25.0 g/day
CLP and control groups, and no constipation was reported
for any of the subjects on CLP, but it was reported for 2
subjects in the control group. All adverse events were
mild to moderate in severity, tended to be transient, and
resolved without pharmacologic intervention.
Hematology, clinical chemistries, and other safety
assessments
No clinically significant changes in mean hematology
values were observed in any treatment group. With the
exception of the serum carbon dioxide concentration
(CO2), there were no noteworthy changes in mean clin-
ical chemistry values. As shown in Figure 5, serum CO2
decreased as the dose of the acidic CLP polymer in-
creased, and in the 25.0 g/day CLP group, fell below thessium following CLP treatment and untreated control. Values are
exposure.
Figure 4 Mean (standard deviation) urine content of sodium
and potassium following CLP treatment and untreated control.
Values are daily averages from Days 5-9, the time period reflective of
steady state CLP exposure.
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until the end of dosing on Day 9. No clinically signifi-
cant changes in urinalysis were observed, and there were
no noteworthy changes in vital signs or ECGs.
Discussion
This Phase 1 study was conducted to evaluate the toler-
ability and effects of three different doses of CLP, a
novel, non-absorbed superabsorbent polymer, on fecal
weight and fecal and urine ion content. No serious
adverse events occurred in the 25 subjects studied. At
CLP doses below 25.0 g/day, there was a low incidence
of self-resolving, mild adverse events. The 25.0 g/day
dose immediately prior to meals caused more gastro-
intestinal adverse events, which resulted in 2 subjects
discontinuing the study medication. There was no clin-
ically meaningful difference between groups who re-
ceived 15.0 g/day CLP under fasting and fed states on
any endpoint. Fecal weight, sodium and potassium in
the stool were increased relative to control in a dose-
related fashion, with a 15.0 g dose removing approxi-
mately 3.0 mEq of sodium and 3.4 mEq of potassium
per gram of polymer. Serum potassium and serum so-
dium concentrations were within the normal range forTable 1 Mean serum ion concentrations during study days 5-
CLP Do
7.5 (n = 5) 15.0 (Fed) (n = 4)
Sodium (mmol/L) 141.1 (1.4) 138.5 (1.8)
Potassium (mmol/L) 4.6 (0.3) 4.3 (0.3)
Magnesium (mmoL/L) 0.8 (0.0) 0.8 (0.0)
Calcium (mmol/L) 2.4 (0.0) 2.3 (0.1)
Phosphorus (mmol/L) 1.5 (0.2) 1.4 (0.1)
Values are the mean (standard deviation) of daily averages from Days 5-9.all subjects, with the 25.0 g/day CLP group showing a
borderline low potassium level. Serum CO2 decreased
as the dose of CLP increased; however, only for the
25.0 g/day CLP group did the serum CO2 fall below the
normal range (23-32 mmol/L).
While there were small changes in fecal phosphorus
content, this was considered clinically inconsequential.
The reduction in urine sodium and potassium is consid-
ered to reflect a normal homeostatic compensation of
the kidney for the loss of these cations in the stool [15].
Previous studies with cation exchange resins in the
treatment of patients with heart failure and fluid over-
load demonstrated removal of sodium and potassium via
the gastrointestinal route [12]. However, these products
failed to achieve a significant therapeutic presence for
fluid management, due to the high doses required (up to
150 g/day), problems in taking the large amounts of un-
palatable resins, significant abdominal side effects and
the advent of loop diuretics. The much higher cation
binding capacity of CLP may offer the opportunity to re-
move up to 1.0 g of sodium with a lower dose of drug,
improving efficiency and gastrointestinal tolerability.
Moreover, the superabsorbent water binding capacity of
CLP allows for direct fluid removal via the fecal route
without causing diarrhea.
Removal of sodium and fluid in the feces may prove
beneficial in patients with kidney failure and fluid over-
load, as well as in those with heart failure and CKD where
the effectiveness of diuretics is limited and diuretic resist-
ance is an increasing problem [2,7-9]. High dietary sodium
intake has been implicated in target organ damage in kid-
ney and heart cells via increases in blood pressure and oxi-
dative stress, reduction of arterial elasticity and fibrotic
cell remodeling [16]. Dietary sodium restriction is recom-
mended in the management of hypertension, heart failure
and CKD [16-18]. Studies have shown the beneficial ef-
fects of dietary sodium reduction to lower blood pressure
and reduce deaths from heart attack and stroke [19,20]. In
patients with salt sensitive treatment resistant hyperten-
sion, systolic blood pressure reductions of over 20 mmHg
have been reported after dietary sodium restriction [21].
Sodium reduction also lowered proteinuria in chronic
kidney disease patients [22]. However, dietary sodium9 by treatment group
se (g/day) Control (n = 5)
15.0 (Fasted) (n = 5) 25.0 (n = 5)
141.0 (2.6) 137.4 (1.6) 139.4 (1.6)
4.3 (0.4) 3.7 (0.2) 4.8 (0.5)
0.8 (0.0) 0.7 (0.0) 0.9 (0.0)
2.4 (0.1) 2.3 (0.1) 2.4 (0.1)
1.3 (0.1) 1.2 (0.1) 1.6 (0.2)
Figure 5 Mean serum carbon dioxide (CO2) concentration for each treatment group by study day. Dashed lines represent the normal
range (23-32 mmol/L).
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of CLP could remove a clinically meaningful amount of
sodium from the systemic circulation [23].
The fecal removal of up to 2.0 g potassium from the body
may have desirable benefits for patients at risk for hyperka-
lemia such as CKD or heart failure patients, especially pa-
tients with a glomerular filtration rate of ≤ 60 mL/min
who have a higher risk for the occurrence of hyperkalemia
[24]. Kayexelate (polystyrene sulfonate), the only approved
potassium removing agent, has significant tolerability and
safety concerns which would render it inadequate to treat
hyperkalemia on a chronic use basis [25,26]. Recently, a
study with RLY5016 has demonstrated that hyperkalemia
may be prevented with a potassium binding oral polymer
[14]. However, in a previously reported Phase 2, double-
blind, placebo-controlled study in heart failure patients,
no differences were observed between CLP and placebo in
serum potassium concentrations. This may have been the
result of the concomitant administration of an aldosterone
antagonist, which alters serum potassium balance [13].
The main weakness of this study is that the small
number of study subjects in each group does not permit
formal statistical analysis of differences between groups.
A strength of the study is the rigor with which subjects
were selected and monitored as inpatients in a metabolic
study unit with strict control of total dietary caloric, ion
and fluid intake and collection of urine and fecal samples
for the duration of the study.
Conclusions
In this study of healthy volunteers, CLP increased fecal
weight and fecal sodium and potassium content in a
dose-related manner, and doses below 25.0 g/day were
well tolerated, with infrequent, self-limiting gastrointes-
tinal adverse events. CLP may represent a new therapeutic
tool for the removal of fluid, sodium and potassium viathe gastrointestinal tract in patients with fluid and sodium
overload in conditions such as congestive heart failure, salt
sensitive hypertension, CKD and end stage renal disease.
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